Skip to main content
. 2016 Nov 28;22:4612–4622. doi: 10.12659/MSM.897702

Figure 6.

Figure 6

The expression levels of CXCL13 protein and mRNA after 3 days of intrathecally administering drugs (saline, anti-CXCL13, or rmCXCL13) were measured by Western blot and RT-qPCR, respectively. S+saline group: rats underwent sham operation and were injected with saline; BM+saline group: rats with bone cancer pain morphine tolerance and injected with saline; BM+rmCXCL13 group: BM rats injected with rmCXCL13; BM+anti-CXCL13 group: BM rats injected with anti-CXCL13 neutralizing antibody. (A) The expression of CXCL13 mRNA after intrathecally administering drugs was examined by RT-qPCR. (B) The expression of CXCL13 protein after 3 days of intrathecally administering drugs was examined by Western blot. (C) The comparisons of CXCL13 mRNA expression among the 4 groups; (D) The comparisons of CXCL13 protein expression among the 4 groups. * Compared with S+saline group, P<0.05; # Compared with BM+saline group, P<0.05; & Compared with BM+rmCXCL13 group, P<0.05.